ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 HKD | -4.64% |
|
+9.51% | -56.63% |
| 05/06 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
| 05/06 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 37Cr | - | |||||
| 5.93TCr | - | |||||
| 4.02TCr | ||||||
| 3.99TCr | ||||||
| 2.86TCr | ||||||
| 2.73TCr |
- Stock Market
- Equities
- 9966 Stock
- Charts Alphamab Oncology
- Sector Chart
